Skip to main content
Fig. 3 | Experimental Hematology & Oncology

Fig. 3

From: Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Fig. 3

T-cell redistribution during treatment week 1 coincides with activation of LFA-1 and upregulation of CD69. Boxplots depicting the CD3+ T-cell counts of patients with frequent blood sampling during the 1st week after start of infusion in cycle 1 (a), the percentage of CD3+ T cells with activated (i.e., intermediate affinity) LFA-1 (b), the percentage of CD8+ CD69+ (c), and CD4+ CD69+ T cells (d). Black line median values; plus sign mean values. Boxes extend from the 25th to 75th percentile, with bars extending to the minimum and maximum values within 1.5 times the interquartile range (difference between the 25th and 75th percentile). Corresponding patient numbers are shown in Additional file 3

Back to article page